Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction

American Journal of Clinical Nutrition

Volumn 64, Issue 1, 1996, Pages 7-11

  Calles Escandon, Jorge ^a   Ballor, Douglas ^a   Harvey Berino, Jean ^a   Ades, Philip ^a   Tracy, Russell ^a   Sobel, Burton ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Atherosclerosis; coronary disease; elderly people; obesity

Indexed keywords

ANTIPLASMIN; PLASMIN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; CALORIC INTAKE; CALORIC RESTRICTION; CORONARY ARTERY DISEASE; DIET RESTRICTION; DRUG BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; VASCULAR DISEASE;

EID: 0029987435     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/64.1.7     Document Type: Article

References (53)

1. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
3. Kissebah AH, Vydelengum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54:254-60.
4. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989;2:419-23.
5. Lapidus L, Bengtsson C, Larson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of 1462 women in Gothenburgh, Sweden. Br Med J 1984;289:1257-61.
6. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-9.
7. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
8. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993;13:1865-73.
9. Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 1993;10:638-42.
10. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993;42:945-9.
11. Gray RP, Paterson DL, Yudkin JS. PAI activity in diabetic and nondiabetic survivors of MI. Arterioscler Thromb 1993;13:415-20.
12. Niwano H. Behaviour of tPA, PAI-1 and their complex in various disease states. Diabet Med 1992;3:389-93.
13. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 1993;13:1412-7.
14. Sawdey MS, Lockutoff DJ. Regulation of murine type I plasminogen activator by inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor alpha and transforming growth factor beta. J Clin Invest 1994;88:1346-51.
15. Marongier F, Conti M, ManelSorano GG, Cossei E, Cirillo E, Balestrieri A. Is the imbalance between thrombin and plasmin activity in diabetes related to the levels of antiplasmin activity? Thromb Res 1994;58:99-109.
16. Juhan-Vague I, Vague P, Alessi MC, et al. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab Rev 1987;13:331-6.
17. Seljeflot I, Entstand J, Torjesen P, Arnesen H. Insulin and PAI-1 levels during an oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest 1994;54:241-6.
18. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993;36:817-25.
19. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990;39:1044-8.
20. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A 1991;88:9959-63.
21. Nordt TK, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 (PAI-1) by precursors of insulin: a potential risk factor for vascular disease. Circulation 1994;89: 321-30.
22. Sawa H, Nordt T, Sobel B, Fuji S. Production of type-1 plasminogen activator inhibitor by adipocytes: its implications for cardiovascular risk associated with obesity. Circulation 1994;90:1-57(abstr).
23. Boden G, Chen X, DeSantis RA, Kendrick Z. Effects of age and body fat on insulin resistance in healthy men. Diabetes Care 1993;16:728-33.
24. Kohrt WM, Kirwan JP, Staten MA, Bourey RE, King DS, Holloszy JO. Insulin resistance in aging is related to abdominal obesity. Diabetes 1993;42:273-81.
25. Pellegrini RV, Di Marco RF, Werner AM, Marrangoni AG. Recurrent ischemic heart disease: the effect of advancing age. J Cardiovasc Surg 1994;35:371-6.
26. Tallarida RJ. Current and historical mortality from cancer and cardiovascular disease in relation to age: U.S. and world values. Life Sci 1994;56:PL51-62.
27. Tremblay A, Despres JP, Maheux J, et al. Normalization of the metabolic profile in obese women by exercise and a low fat diet. Med Sci Sports Exerc 1991;23:1326-31.
28. Jeffery RW, Gray CW, French SA, et al. Evaluation of weight reduction in a community intervention for cardiovascular disease risk: changes in body mass index in the Minnesota Heart Health Program. Int J Obes Related Metab Disord 1995;19:30-9.
29. Folsom A, Qamhieh HT, Wing R, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factor in moderately overweight adults. Arterioscler Thromb 1993;13:162-9.
30. Gris JC, Schved JF, Feugeas O, et al. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men. Thromb Haemost 1990;64:516-20.
31. Parenti M, Palareti G, Babini AC, Poggi M, Torricelli P, Melchionda N. Effect of slimming on metabolic and haemorrhagic patterns in a group of obese subjects. Int J Obes 1988;12:179-84.
32. Baron J, Mann J, Stukel T. Effect of weight loss on coagulation factors VII and X. Am J Cardiol 1989;64:519-22.
33. Ditschuneit H, Fletcher-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res 1995;3:43-8.
34. Primrose JN, Davies JA, Prentice RM, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992;68:396-9.
35. Sylvan A, Rutegard JN, Janunger KG, Sjolund B, Nilsson T. Normal plasminogen activator inhibitor levels at long-term follow up after jejuno-ileal bypass surgery in morbidly obese individuals. Metabolism 1992;41:1370-2.
36. Vene N, Stegnar M. Tissue-type plasminogen activator and plasminogen activator inhibitor-1 after exercise: comparison to venous occlusion and DDAVP. Fibrinolysis 1990;4(suppl 2):105-7.
37. Gris JC, Schved JF, Aguilar-Martinez P, et al. Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 1990;4(suppl 2):97-8.
38. Williams RS, Logue EE, Lewis JL, et al. Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. N Engl J Med 1980;302:987-91.
39. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-59.
40. Sin WE. Body composition from fluid spaces and density: analysis of methods. In: Brozek J, Henschel A, eds. Techniques for measuring body composition. Washington, DC: National Academy of Sciences 1961:223-44.
41. Declerck P, Alessi M, Verstreken M, Kruithof E, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzymelinked inmunosorbent assay. Blood 1988;71:220-5.
42. Holvoet P, Cleemput H, Colled D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985;54:684-97.
43. Alessi M, Juhan-Vague I, Declerck P, Anfoso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res 1990;60:509-16.
44. 2-antiplasmin complex in human plasma - application for the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986;56:124-7.
45. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
46. Klassen KJ, Nordt TK, Schneider DJ, Sobel BE. Constitutive biosynthesis of plasminogen activator inhibitor type 1 (PAI-1) by cultured human aortic endothelial cells independent of insulin. Coron Artery Dis 1993;4:713-9.
47. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993;13:1822-8.
48. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 1991;229:309-16.
49. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992;41:890-5.
50. Ernst E, Weihmayr T, Matrai A, Resch KL. Changes in blood rheology of grossly obese individuals during a very low calorie diet. Int J Obes 1989;13:167-8.
51. Mehrabian M, Peter J, James Barnard R, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990;84:25-32.
52. Fisler JS. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr 1992;56(suppl):230S-4S.
53. Hamouratidis ND, Pertsinidis TE, Bacharoudis GP, Papazachariou GS. Effects of exercise on plasma fibrinolytic activity in patients with ischaemic heart disease. Int J Cardiol 1988;19:39-45.